Search

Displaying results 931 - 940 of 10000 in total
  1. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Sorbitol

    go.drugbank.com/drugs/DB01638
    ApprovedInvestigational

    It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures. … A polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is also produced synthetically from glucose.

    Mixtures: INFUSOL M20S (Mannitol 17.5%w/v and Sorbitol 2.5%w/v Intravenous Infusion)Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe malabsorption. … Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group. Xylose is a sugar isolated from wood.

  4. Drug

    PF-5190457

    go.drugbank.com/drugs/DB14870
    Investigational

    PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).

  5. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors … , while delivering enhanced anti-tumor activity, with an improved safety profile.

    Synonyms: PD-L1/4-1BB bispecific antibody
  6. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    It is marketed as Galvus.[L32803] Vildagliptin is also available as Eucreas, a fixed-dose formulation with metformin for adults in who do not adequately glycemic control from monotherapy. … [L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia.

    Categories: P-glycoprotein substrates, DPP-IV Inhibitors
  7. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  8. Drug

    Lorazepam

    go.drugbank.com/drugs/DB00186
    ApprovedInvestigational

    Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic.

  9. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes

  10. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.